Media Contact:
Stephen Majors
Vice President, Global Communications
smajors@alliancerm.org
Brussels, BE
The EU Health Technology Assessment (HTA) Coordination Group’s ‘Methodological Guideline for Quantitative Evidence Synthesis: Direct and Indirect Comparisons’ is discouraging news for rare disease patients and the Advanced Therapy Medicinal Products (ATMP) sector.
Washington, DC
The voluntary model recognizes that transformative, durable, and potentially curative gene therapies require innovative thinking about access, payment, and healthcare delivery.
Washington, DC
Today, the FDA approved two gene therapies to treat sickle cell disease, marking the biggest day in the history of gene therapy and a seminal moment in the history of biotechnology and human health.
Carlsbad, CA
New analysis shows that durable cell and gene therapies have clinical success rates between two and three times higher than other types of treatments.
